Biological
TBio-4101
TBio-4101 is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Completed1
Terminated1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
completed133%
terminated133%
active_not_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
completedphase_1
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
NCT05628883
active_not_recruitingphase_1
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
NCT06236425
terminatedphase_1
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
NCT05576077
Clinical Trials (3)
Showing 3 of 3 trials
NCT05628883Phase 1
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
NCT06236425Phase 1
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
NCT05576077Phase 1
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3